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Metabolic  diseases  that  involve  the  liver  represent  a heterogeneous  group  of disorders.  Apart  from  the
metabolic  defect,  the  subject’s  liver functions  may  be normal.  With  the  increasing  need  for organs,  liversccepted  6 November 2014
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from  donors  with  metabolic  diseases  other than  familial  amyloid  polyneuropathy  might  be  possibly  used
for  transplantation.  However,  whether  such  livers  qualify  as grafts  and  how  they  might  impact  recipient
outcome  are  still  unanswered  questions.  This  review  of the  literature  summarizes  current  experience  in
the  use  of such  grafts  in the  context  of cadaveric,  domino,  and  living-related  liver  transplantation.
© 2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  
ND licnusual grafts
. Introduction
Metabolic diseases that involve the liver represent a hetero-
eneous group of disorders. Some of these liver-based genetic
isorders are characterized by liver parenchyma damage and
ltered hepatic function, while others by structurally normal liver
nd relatively preserved liver function. These disorders can be
ured, or at least improved, by liver transplantation (LT) [1]. Among
he different metabolic diseases, the use of livers from carriers of
amilial amyloid polyneuropathy for domino liver transplantation
DLT) has been well described and constitutes an established pro-
edure in endemic areas. However, whether livers affected by other
etabolic diseases qualify as grafts in the context of cadaveric liver
ransplantation (CLT), DLT, or living-related liver transplantation
LRLT), and how they might impact outcome in the recipient are
till unanswered questions.
Open access under CC BY-NC-A  discussion of all types of hepatic metabolic disorders that
ight be present in liver grafts is beyond the purpose of this
eview. The principal clinical features of the metabolic disorders
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ax: +33 171 97 01 57.
E-mail  addresses: astrid.schielke@psl.aphp.fr (A. Schielke),
lomena.conti@psl.aphp.fr (F. Conti), clairegoumard@hotmail.fr (C. Goumard),
abiano.perdigao@psl.aphp.fr (F. Perdigao), yvon.calmus@psl.aphp.fr (Y. Calmus),
livier.scatton@psl.aphp.fr (O. Scatton).
ttp://dx.doi.org/10.1016/j.dld.2014.11.004
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Otargeted here are summarized in Table 1. This review of the litera-
ture addresses the issue of using such grafts in the context of CLT,
DLT, and LRLT, and the outcome in recipients (Tables 2–5).
2.  Metabolic disorders in CLT
2.1. Donor screening for rare metabolic disorders in CLT
In  cadaveric liver donation, no guidelines exist on the screening
of donors for rare metabolic disorders. The clinical context of the
potential donor is usually an emergency situation, with a brief time
frame for screening procedures. To detect metabolic diseases, cli-
nicians need to be aware of unusual clinical signs before death –
especially in young donors – such as neurological impairment or
deteriorating kidney function. Family history is crucial to direct
diagnostic screening towards hereditary metabolic disorders, and
should include unexplained neurological signs in family members,
renal impairment, and thromboembolic events. Imaging studies
such as computed tomography or MRI  could be useful tools to
detect unusual hepatomegaly, signs of metabolic storage disease
with iron overload in the liver in the case of haemochromatosis, or
early atherosclerosis in familial hypercholesterolemia. It is difﬁcult
to analyze abnormalities in routine coagulation tests of the donor
in the context of an unstable donor with disseminated intravas-
ense.cular coagulation requiring the infusion of fresh frozen plasma.
Some disorders with high carrier rates such as factor V Leiden
mutation, alpha-1 antitrypsin deﬁciency, or haemochromatosis
have been proposed for inclusion in systematic donor screening.
pen access under CC BY-NC-ND license.
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Table 1
Principal clinical features of rare hereditary metabolic disorders.
Hereditary disease Transmission Predominant clinical feature Treatment
Nephropathy
Non-TTR amyloidosis
Fibrinogen A -chain amyloidosis Autosomal-dominant Progressive renal failure SLKT
Apolipoprotein AI amyloidosis Autosomal-dominant Progressive renal failure KT
Lysozyme  amyloidosis Autosomal-dominant Hepatomegaly, renal failure,
digestive  symptoms, sicca
syndrome
LT
Hyperoxaluria Autosomal-recessive Nephrocalcinosis, renal failure SLKT
Neuropathy
Urea  cycle disorder
Carbamylphophatase synthetase 1 Autosomal-recessive Hyperammonemia, brain oedema Diet, LT “case by case”
Ornithin transcarbamylase deﬁciency X-linked Hyperammonemia Diet, LT “case by case”
Citrullinemia type II Autosomal-recessive Hyperammonemia Diet, if failure LT
Organic  aciduria
Maple  syrup disease Autosomal-recessive Ketoacidosis Medical treatment and diet
Methylmalonic academia Autosomal-recessive Encephalopathy, seizure, coma
Propionic academia Autosomal-recessive Hyperammonemia
Hepatic  Porphyria
Acute  Intermittent Porpyria Autosomal-dominant Neurovisceral attacks LT
Erythropoietic Protoporphyria Autosomal-dominant Photosensitivity Medical treatment, LT
Storage disease
Metal  storage disorder
Hereditary  Haemochromatosis Autosomal-recessive Heart failure, liver cirrhosis,
diabetes
Phlebotomy
Wilson’s disease Autosomal-recessive Liver failure, neuropsychiatric
manifestations
LT
Glycogen  storage disorder
All  types but IXa Autosomal-recessive Hepatomegaly, hypoglycemia,
seizures,  liver adenoma, HCC
Diet, LT
IXa  X-linked
Familial Hypercholesterolemia Autosomal-dominant Early atherosclerosis,
cardiovascular events
Medical treatment
Hepatopathy
Bilirubin  metabolism disorders
Crigler–Najjar Syndrome Autosomal-recessive Jaundice, kernicterus in neonatal
form
LT
Gilbert  Syndrome Autosomal-recessive Jaundice None
Progressive Familial Intrahepatic Cholestasis Autosomal-recessive Portal hypertension, pruritus, HCC LT
Alagille  Syndrome Autosomal-dominant Bile duct paucity LT
Coagulation disorder
Factor  V Leiden Autosomal-recessive Thromboembolic events Preventive anticoagulation
Protein  C deﬁciency Autosomal-recessive Thromboembolic events
Protein S deﬁciency Autosomal-recessive Thromboembolic events
Haemophilia A X-linked Haemorrhage Factor substitution
Factor  VII deﬁciency Autosomal-recessive Prolonged aPTT
Factor XI deﬁciency Autosomal-recessive Prolonged aPTT
Factor XII deﬁciency Autosomal-recessive Prolonged aPTT
Other metabolic diseases
Thyrosinemia  type I Autosomal-recessive HCC Medical treatment
Alpha-1  antitrypsin deﬁciency Autosomal-recessive Lung emphysema, liver cirrhosis Lung and LT
H ; RLT
H
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aPseudoxanthoma  elasticum Unclear 
CC, hepatocellular carcinoma; KT, kidney transplantation; LT, liver transplantation
owever, time remains the principal obstacle to extensive
creening in the context of cadaveric donation; besides, trans-
ission of these rare diseases will remain unpredictable and
navoidable, and could have a potentially fatal outcome in some
ecipients. Also, no informed consent can be obtained from the
ecipients to accept a graft with a rare metabolic disorder that might
mpact their future quality of life. If the diagnosis of an acquired
etabolic disease is made after LT, speciﬁc information and follow-
p of the recipients are mandatory. Repeated transplantation might
e discussed in selected cases, while balancing the metabolic risk
gainst the operative risk of repeating surgery.Skin and eye lesions, vascular
occlusive  disease
Medical treatment
, re-transplantation; SLKT, synchronous liver-kidney transplantation.
2.2.  Inadvertent use of affected grafts in CLT with prolonged
recipient survival (Table 2)
2.2.1. Haemochromatosis
Hereditary haemochromatosis causes progressive iron overload
with parenchymal damage to the liver, pancreas, and heart. Its
prevalence is about 0.5%, with a heterozygous carrier frequency
of about 10% [1]. In CLT, the inadvertent use of homozygous grafts
carrying the C282Y mutation has been reported [2–5]. The resulting
progressive iron overload in the recipient was  managed by repeated
phlebotomy [6]. The longest follow-up period reported is 8 years
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Table  2
Inadvertent use of affected grafts in cadaveric liver transplantation and recipient outcomes.
Hereditary disease No. of cases Recipient outcomes
Inadvertent use of affected grafts in CLT with prolonged recipient survival
Hereditary Haemochromatosis 18 Repeat phlebotomy for iron overload [6], 1 cirrhosis after 4 years [3],
longest follow-up 8 years
Gilbert syndrome 5 Good long-term outcome [8]
Factor VII deﬁciency 1 Prolonged aPTT, no bleeding episodes reported [9–11]
Factor XI deﬁciency 1
Factor  XII deﬁciency 1
Alpha-1 antitrypsin deﬁciency 6 1 developed cirrhosis and panniculitis at 1.5 years requiring RLT, 1
mild ﬁbrosis on biopsy at 6y follow-up [13,14]
Pseudoxanthoma elasticum 3 Developed skin lesions, no long-term follow-up reported [15]
Inadvertent and discouraged use of affected grafts in CLT
Ornithine  transcarbamylase deﬁciency 3 All fatal: hyperammonemia, coma in two [16,18], fatal pneumonia
after  initially successful MARS treatment in one [19]
Factor V Leiden 2 Deep vein thrombosis in one, hepatic artery thrombosis and RLT
[20,21]
Protein C deﬁciency 2 Thrombotic events [22,23]
Protein S deﬁciency 1 Hepatic artery thrombosis requiring RLT, fatal outcome due to fungal
sepsis [24]
Haemophilia A 2 Haemorrhage requiring RLT in one [25], potential extrahepatic factor
VIII production and no bleeding episodes in one donor with a mild
phenotype [26]
CLT, cadaveric liver transplantation; m,  months; y, year; RLT, re-transplantation.
Table  3
Use  of affected grafts in domino liver transplantation and recipient outcomes.
Hereditary disease No. of cases Recipient outcomes
Use of affected grafts in DLT with good recipient outcomes
Fibrinogen  A -chain amyloidosis 4 No renal failure at 5 years of follow-up [29]
Maple  syrup disease 9 Good long-term outcome [30–33]
Familial hypercholesterolemia 2 Longest follow-up 7 years, elevated plasma cholesterol resistant to medication and autologous
stem cell transplantation in one [34–36]
Discouraged use of affected grafts in DLT
Hyperoxaluria 8 Fatal in four cases due to rapidly developing renal failure [38], one RLT for hepatic artery
thrombosis [38], one RLT for rapid progressive renal failure [41]
Acute Intermittent Porphyria 3 One fatal, two  with sensimotory neuropathy and abdominal pain [44]
Thyrosinemia type I Not  described Toxic metabolites inducing apoptosis in hepatocytes with risk of HCC in up to 75% of explants
[45]
Apolipoprotein  A1 Amyloidosis Not described Hepatomegaly with extensive amyloid inﬁltration, not suitable for DLT [46,47]
Lysozyme Amyloidosis Not described Hepatomegaly with spontaneous hepatic rupture or haematoma in three cases [48], not
suitable for DLT
DLT, domino liver transplantation; HCC, hepatocellular carcinoma; m,  months; y, year; RLT, re-transplantation.
Table  4
Use  of heterozygous grafts in living-related liver transplantation and recipient outcomes.
Hereditary disease Donor status and recipient outcomes
Primary Hyperoxaluria SLKT from the same donor, longest follow-up 12 m [46–49]
Familial Hypercholesterolemia Longest follow-up 6y, cholesterol levels controlled under medication [50–52]
Carbamylphophatase synthetase 1 Normal diet, longest follow-up 2.5 years [53]
Ornithin transcarbamylase deﬁciency Heterozygous asymptomatic female donors are possible [55,56]
Citrullinemia type II Good neurological status [58–60]
Maple Syrup Urine Disease No metabolic decompensation at 13 months [61]
Methylmalonic academia Neurological improvement, but medication maintained [54,55]
Propionic academia Partial correction of metabolic disorder [62]
Erythropoietic protoporphyria Fatal outcome after 3.3 m due to bile leakage and candidosis [64]
Haemochromatosis Liver function tests normal at 1y follow-up [65]
Wilson’s  disease Heterozygous donors present intermediate copper metabolism, but good results in recipients [69]
Glycogen storage disorder types I and III Correction of hypoglycaemic episodes and normalization of growth [72,73]
Crigler–Najjar Syndrome Longest follow-up 34 m,  normal neurological development [64]
Progressive Familial Intrahepatic Cholestasis Good results in type2, heterogeneous results in type 1 [75,76]
Alagille Syndrome Good results after donor bile duct evaluation [77,78]
Alpha-1-antitrypsin deﬁciency No data on donor genetic status and follow-up [79,80]
Thyrosinemia type I Good results [54,64]
SLKT, synchronous liver-kidney transplantation; m,  months; y, year.
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Table 5
Protocol for donor evaluation prior to a living donation.
Screening variables in donation candidates Donation possible
Blood group
ABO  and irregular antibodies Within compatible
blood  groups
Assessment of liver volume and anatomy
Liver volume sufﬁcient for donor and recipient No if abnormal
Vascular and biliary anatomy compatible with
donation
No if abnormal
Normal liver parenchyma in donor Biopsy if abnormal
Transmissible diseases
Hepatitis  B Yes, protocol for
anti-HBs/anti-HBc
antibody  positive donors
Hepatitis  C Yes, protocol for
anti-HCV  antibody
positive  donors
HIV No
Cancer  No
Standard  blood tests Further investigation if
abnormal
Complete  blood count: red and white blood cells,
platelets, haemoglobin, hematocrit
Blood biochemistry tests: BUN, creatinine,
electrolytes, lipid proﬁle, glucose, Hb1Ac
Liver function tests: AST, ALT, ALP, GGT, Bilirubin
Coagulation tests and thrombophilia
PT, aPTT, INR, ﬁbrinogen Further investigation if
abnormal
Factors  II,V,VIII, VII + X
Platelet function assay No
Activated  protein C resistance No
Genetic  testing for mutation of factor II and factor
V  Leiden
No
Antithrombin III, Protein S No
Antiphospholipid  antibodies IgG and IgM No
Other
EBV  serology, CMV  serology, Toxoplasma,
Treponema pallidum particle
haemagglutination  test
Yes
Yes
Source: Modiﬁed from [49].
BUN, blood urea nitrogen; Hb1Ac, glycated haemoblobin; AST, aspartate amino-
transferase;  ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT,
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tamma-glutamyl transpeptidase; PT, prothrombin time; aPTT, activated partial
hromboplastin time; EBV, Epstein–Barr Virus; CMV, cytomegalovirus; HCV, hep-
titis C virus; HIV, human immunodeﬁciency virus; HB, hepatitis B.
7]. One recipient developed cirrhosis during a 4-year follow-up
eriod [3], but there have been no reports of re-transplantation for
cquired haemochromatosis.
.2.2.  Gilbert syndrome
Isolated  cases of unconjugated hyperbilirubinemia acquired by
iver transplant recipients from undiagnosed donors with Gilbert
yndrome have been reported. In this syndrome the gene defect is
esponsible for a UDP-glucuronosyltransferase-1A1-deﬁciency in
he liver. The incidence of this condition among LT recipients is 2.6%
8]. None of these recipients experienced an impaired long-term
utcome or other graft dysfunctions. This is a benign condition and
he use of affected livers in the context of CLT seems to be possible
ithout restriction.
.2.3.  Bleeding disorders
Three  recipients have been reported to have presented with iso-
ated prolonged aPTT after LT. Acquired factor XII [9], factor VII [10],
nd factor XI [11] deﬁciencies were found to have been transmit-
ed via an affected graft, but none of the recipients showed any
vidence of bleeding during follow-up. The long-term outcomes of
hese reported cases are unknown, but in the case of isolated factorr Disease 47 (2015) 261–270
disorders  other than haemophilia, the use of the graft seems to be
possible.
2.2.4. Alpha-1-antitrypsin deﬁciency
The incidence of a mutation in the hepatic protease inhibitor
alpha-1-antitrypsin ranges from 1 per 2500 live births in Europe to
1 per 1500 in the USA [1], with variable penetrance. A population-
based study showed that signiﬁcant liver disease was  only found in
10–15% of the children with the homozygous PiZZ phenotype [1].
About 10% of adults will develop cirrhosis during their fourth or ﬁfth
decade of life, which is frequently associated with cofactors such as
viral or alcoholic hepatitis [1]. In one series, the Z allele was  found in
0.8% of presumed healthy donor livers [12]. There have been several
reports of acquired alfa-1-antitrypsin deﬁciency following CLT. One
recipient of a graft with the PiZZ phenotype developed symptoms
of cirrhosis and panniculitis 18 months after LT. The skin lesions
resolved completely within three weeks of re-transplantation [13].
In another case of a graft with the PiZZ phenotype, the recipient
was followed for 6 years and a biopsy revealed mild chronic por-
tal hepatitis and portal ﬁbrosis [14]. In three other cases, including
two heterozygeous MS  and MZ phenotypes and one homozygeous
ZZ phenotype from undiagnosed donors, biopsies showed PAS-
diastase resistant globules in the recipients, without there being
any impact on allograft function, although this was  after a limited
follow-up period [6].
2.2.5.  Pseudoxanthoma elasticum
Pseudoxanthoma elasticum is a metabolic disorder that results
from mutations in the gene encoding the cellular transporter
ABCC6, which is primarily expressed in the liver and kidney. The
mode of inheritance is not clear, but it might be autosomal reces-
sive or autosomal dominant in some cases [15]. The mineralization
of dystrophic elastic ﬁbres in the dermis, retina, and internal
elastic lamina of medium-sized arteries has been observed. The
clinical picture is characterized by skin lesions affecting the neck
and ﬂexural creases, subretinal choroidal neovascularization with
subsequent haemorrhage in the eyes, and premature peripheral
vascular, coronary artery, and cerebrovascular occlusive disease
[15].
There have been reports of three patients who developed
characteristic skin lesions and histopathological evidence of pseu-
doxanthoma elasticum after LT, suggesting that this disease might
have been acquired from the transplanted organ [15]. No data on
their long-term follow-up or outcomes have been reported.
2.3.  Inadvertent and discouraged use of affected grafts in CLT
(Table  2)
2.3.1.  Ornithine transcarbamylase deﬁciency
Ornithine transcarbamylase deﬁciency (OTC) is an X
chromosome-linked disorder that interferes in the initial two
steps of the urea cycle (see paragraph III-4 and Table 1). There
have been three case reports of acquired OTC deﬁciency following
LT from deceased undiagnosed male donors[16–18]. The outcome
was fatal in all three recipients due to rapid hyperammonemia in
two cases and nosocomial pneumonia in the other, after initially
successful MARS treatment [19].
2.3.2. Thrombotic disorders
The  factor V Leiden mutation represents the most common
genetic defect predisposing to venous thrombosis and is found in
up to 10% of the general population [20], followed by protein C and
S deﬁciency. About 90% of factor V is produced by the liver and is
located in the plasma with a half-life of about 24 h. Factor Va is
a cofactor for converting prothrombin to thrombin and is inactiv-
ated by activated protein C. In this mutation, factor Va is resistant
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o inactivation by activated protein C, leading to a hypercoagu-
able state with an accumulation of thrombin. Heterozygosity for
he factor V Leiden mutation increases the lifetime risk of throm-
otic events by 5 to 10-fold, and homozygosity increases it by 50
o 80-fold. Acquired factor V Leiden thrombophilia after LT has
een reported [20,21]. One recipient exhibited recurrent deep-vein
nd portal vein thrombosis after receiving a liver from an undi-
gnosed donor with a homozygous factor V Leiden mutation [20].
epatic artery thrombosis and a subsequent liver abscess requiring
e-transplantation were reported in another undiagnosed recipi-
nt [21]. Biopsies of both native and donor livers were analyzed by
CR and revealed heterozygosity for the factor V Leiden mutation
n both the donor and recipient [21]. One in 20 cadaveric donors
re likely to be heterozygous for the factor V Leiden mutation,
nd questions regarding the routine screening of donors have been
aised [20,21]. Screening for thrombophilia in recipients might be
iscussed in order to avoid matching of a heterozygous recipient
ith a heterozygous donor for factor V Leiden mutation.
In  the literature, there are two case reports of heterozygous pro-
ein C deﬁciency [22,23] and one case of heterozygous protein S
eﬁciency that were acquired from undiagnosed donors [24], both
eading to severe thrombotic complications in the recipients. A fatal
utcome was reported in the recipient with the acquired protein
 deﬁciency that underwent re-transplantation but died from fun-
al sepsis [24]. Unexplained thrombotic events in CLT recipients,
ncluding hepatic artery thrombosis or deep-vein thrombosis with
o prior history of thrombophilia, should encourage speciﬁc efforts
o search for a hypercoagulable disorder acquired via an undiag-
osed donor. In the case of a donor with a known heterozygous
hrombophilic disorder, CLT might be considered in selected recipi-
nts with negative screening for thrombophilic disorders. Informed
onsent from the recipient should be obtained and transplantation
f the affected graft should be undertaken with effective anticoag-
lation in the recipient.
.3.3.  Haemophilia A
Haemophilia A is the most common X-linked bleeding disor-
er, with a frequency of 1 in 5000 to 10,000 male births. There
as been one reported case of acquired haemophilia A after CLT
hat resulted in intra-abdominal haemorrhage requiring repeated
urgery and subsequent re-transplantation [25]. There has also
een one report of potential extrahepatic factor VIII production in
he case of a recipient who received a graft from a donor with known
ild haemophilia. The recipient displayed normal factor VIII levels,
nd no bleeding episodes occurred during follow-up [26].
.  Metabolic disorders in the context of domino liver
ransplantation
.1.  Diagnosis and care of both donor and recipient with rare
etabolic  disorders in DLT
The clinical situation of DLT donation forms part of a planned
trategy for LT, and the diagnosis of a metabolic disorder will have
een established through extensive screening of both donor and
ecipient. The possible impact of such a metabolic disorder on the
ecipient will have been discussed and been the subject of informed
onsent by both donor and recipient. DLT using grafts affected by
etabolic disorders could be an option for recipients who  fulﬁl at
east one of the following conditions: (1) presence of normal sys-
emic enzyme activity that can compensate for the genetic defect
ransmitted by the graft; (2) an expected interval before the onset
f the acquired metabolic disease that is longer than, or at least
quivalent to, the expected survival without LT; and (3) in some
xceptional cases, the need for a bridging treatment while waiting
or a second, healthy graft. Long-term follow-up of the recipient isr Disease 47 (2015) 261–270 265
organized and screening for symptoms must be established. Elec-
tive re-transplantation can be discussed in the case of intractable
clinical symptoms, such as those described in Familial Amyloid
Polyneuropathy [27].
3.2.  Use of affected grafts with good recipient outcome in DLT
(Table  3)
All  these grafts reportedly used in DLT may  also be a graft source
for CLT if the diagnosis is conﬁrmed in the donor prior to donation
and informed consent is obtained from the recipient.
3.2.1. Fibrinogen A ˛-chain amyloidosis
Non-transthyretin amyloidoses are hereditary nephropathies
usually referred to as “non-neuropathic hereditary renal amyloid-
osis”, with an autosomal dominant inheritance and incomplete
penetrance [28].
The  gene mutation in ﬁbrinogen A -chain amyloidosis was ﬁrst
described in 1993. In this context, abnormal ﬁbrinogen production
is exclusively of hepatic origin, leading to rapid and progressive
renal failure within one to ﬁve years of initial presentation, with
proteinuria and hypertension [28]. Atheromatous systemic vas-
cular involvement, with coronary artery disease and myocardial
infarction, may  be present in up to 68% of patients, and parasym-
pathic dysfunction with bradycardia and subsequent pacemaker
insertion is also frequent [29]. The use of four livers for DLT has
been reported: follow-up of the DLT recipients for up to 5 years
did not reveal any evidence of renal impairment [29]. These livers
may therefore qualify as grafts for DLT, even though the long-term
outcome of the recipients remains poorly deﬁned.
3.2.2. Maple syrup urine disease
Maple syrup urine disease is marked by potentially life-
threatening episodes of ketoacidosis (See paragraph III-4 and
Table 1). LT has been performed with satisfactory correction of the
enzymatic disorder and the prevention of long-term neurological
consequences [1]. Reports in the recent literature have described
the safe use of explanted livers for DLT grafts in nine cases with
a good long-term outcome [30–33]. The use of such grafts in the
context of CLT or DLT may  be possible in selected patients, such
as recipients displaying normal systemic enzyme activity; such
patients were reported to be able to ingest a normal diet without
protein restriction [31].
3.2.3.  Familial hypercholesterolemia
The  dysfunction or absence of low-density lipoprotein recep-
tors in affected patients is responsible for the elevated plasma LDL
cholesterol levels and subsequent early atherosclerosis. The ﬁrst
case reporting the use a liver with homozygous familial hyper-
cholesterolemia in DLT was described in 2003 [34]. Long-term
follow-up of the recipient after seven years did not reveal any
cardiovascular impairment, and elevated plasma cholesterol lev-
els were managed with medical treatment [35]. Another case was
reported in 2010, with satisfactory follow-up at ten months [36].
Thus, in DLT the use of grafts from subjects with familial hypercho-
lesterolemia seems to be possible in selected cases.
3.3. Discouraged use of affected grafts in DLT (Table 3)
3.3.1.  Primary hyperoxaluria
Primary  hyperoxaluria is marked by a deﬁciency in alanine-
glyoxylate aminotransferase, a liver-speciﬁc enzyme, resulting in
the overproduction of liver oxalate that is eliminated in the uri-
nary tract, leading to nephrocalcinosis and end-stage renal failure.
The optimum treatment for these patients is combined liver and
kidney transplantation. There has been one report of a domino
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ecipient developing hyperoxaluria 8 months after DLT; neverthe-
ess, with hyper-hydration and medical treatment the patient did
ot develop syptomatic urinary stones [37]. Five other cases using
rimary hyperoxaluria livers for DLT have been reported from the
urotransplant region [38]. The recipients developed early renal
ailure requiring dialysis within 4 weeks of transplantation despite
ood liver graft function. Four of these ﬁve recipients died, and the
nly surviving patient underwent re-transplantation for hepatic
rtery thrombosis, with subsequent improvement in renal failure
38]. Three other cases of DLT developed rapid renal failure requir-
ng haemodialysis in two recipients [39,40]. In one recipient, liver
e-transplantation was performed after the onset of progressive
enal failure and an improvement in kidney function was  observed
hereafter [41]. The use of an affected graft in DLT as a bridge to
eﬁnitive LT in a neonate with factor V Leiden mutation was  also
eported [42,43]. The recipient exhibited good liver graft function
ut experienced rising oxalic acid excretion and an impairment
f renal function with evidence of nephrocalcinosis at 3 months.
iving-related liver re-transplantation was performed at 4 months,
fter which the oxaluria disappeared and renal function normal-
zed [43]. Therefore, the use of homozygous primary hyperoxaluria
ivers for DLT cannot be recommended.
.3.2. Acute intermittent porphyria
The liver-derived heme precursor delta-aminolevulinic acid is
he main cause of potentially life-threatening neurovisceral attacks
n patients with acute intermittent porphyria. LT represents an
ffective treatment for this disorder. There has been a single report
egarding the use of three livers from patients with acute intermit-
ent porphyria in the context of DLT. The two surviving recipients
eveloped sensorimotor neuropathy and recurrent abdominal pain
ue to neurotoxins produced by the graft [44]. The use of affected
rafts for DLT cannot be recommended, as the quality of life of the
ecipients appears to be signiﬁcantly impaired.
.3.3. Tyrosinemia type I
Tyrosinemia type I affects the ﬁnal step of tyrosine and
henylalanine metabolism. Deﬁcient enzymatic activity causes an
ccumulation of toxic metabolites that induces the apoptosis of
idney tubular cells and hepatocytes, and alters hepatocyte DNA,
eading to a major risk for HCC. Affected homozygous organs are
ot suitable for CLT as these livers present a risk of HCC in up to
5% of the explants [45].
.3.4.  Apolipoprotein A1 amyloidosis
Apolipoprotein A1 is a high-density lipoprotein that plays a
rucial role in cholesterol transport and is secreted and metab-
lized by the liver. A defect in the encoding gene generates
eposits of abnormal apolipoprotein leading to late-onset renal
ailure. The clinical presentation may  involve other organs, such
s heart failure and visual impairment. Hepatic involvement may
ause hepatomegaly due to extensive amyloid deposits and ris-
ng alkaline phosphatase concentrations [46,47]. Isolated kidney
ransplantation has enabled an excellent outcome with a follow-
p of up to 27 years [46]. Considering the extensive hepatic
nvolvement, these livers do not seem to be suitable as grafts in
LT.
.3.5. Lysozyme amyloidosis
In  lysozyme amyloidosis, an amyloidogenic precursor of
ysozyme (an ubiquitous bacteriolytic enzyme) is synthesized by
epatocytes and macrophages. The clinical phenotype is heteroge-
eous and may  include gastrointestinal symptoms, sicca syndrome,
urpura and petechiae, and renal failure [48]. Amyloid inﬁltra-
ion of the hepatic parenchyma has been reported at the time
f diagnosis despite preserved liver function. In three cases withr Disease 47 (2015) 261–270
extensive  liver involvement, patients presented with spontaneous
liver rupture [48] and required emergency LT. Despite there have
been no reports in the literature, in view of the extensive hepatic
involvement these livers do not seem to be suitable as grafts for
DLT.
4. Use of heterozygous donors in living-related liver
transplantation (Tables 4 and 5)
4.1. Diagnostic work-up in donor candidates for LRLT
In  the setting of living-related donation, ﬁrst grade relatives
of homozygous carriers of metabolic disorders with autosomal-
recessive inheritance are not affected by the disease and could
be candidates for donation. Among candidates for living-related
donation, genetic and clinical screening for underlying metabolic
disorders is extensively performed, but special attention must also
be paid to possible pre-existing operative risk factors. In France,
screening for thrombophilia is mandatory as part of the proposed
evaluation protocol for living donation candidates (Table 5) [49].
If an hereditary thrombophilia disorder is found in the potential
donor, this candidate will be excluded from planned living-related
donation.
4.2. Primary hyperoxaluria
In  children with primary hyperoxaluria, LRLT combined with
sequential kidney transplantation from the same heterozygous
living-related donor has been reported [50–53]. Urine oxalate
excretion decreased in all cases, and the longest follow-up reported
is twelve months with no evidence of oxalate accumulation in the
renal graft [51]. Heterozygous donors could therefore be considered
in the context of LRLT and could enable a good long-term outcome
in the recipient.
4.3.  Familial hypercholesterolemia
Successful  transplantation with grafts from heterozygous
related donors has been described in three paediatric cases [54–56].
The longest follow-up reported is six years, and plasma cholesterol
levels were controlled in the recipient with an HGM-CoA-reductase
inhibitor [56].
4.4.  Urea cycle disorders
The  urea cycle comprises a series of metabolic pathways, local-
ized mainly in hepatocytes, to detoxify ammonia and convert it
into excretory non-toxic compounds. The overall incidence of urea
cycle disorders is 1:20,000. Enzymatic defects result in an accumu-
lation of highly neurotoxic waste with hyperammonemia. Patients
may also develop severe neurological sequelae and LT is indicated
to prevent their development [1].
4.4.1. Carbamoyl phosphate synthetase 1 deﬁciency
Carbamoyl phosphate synthetase 1 is a mitochondrial matrix
enzyme located in hepatocytes that catalyses nitrogen metabolism
as a ﬁrst step in the urea cycle. The clinical presentation is severe
hyperammonemia with neurological impairment and death from
irreversible brain oedema [57,58]. Affected infants become symp-
tomatic within 72 h of birth; they have a poor prognosis and up
to 76.9% of them die despite medical treatment [57]. LT is indi-
cated to improve their quality of life and reduce neurological
sequelae. Heterozygous grafts for LRLT have been used to correct
this enzymatic defect with satisfactory results in the recipients
[57].
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.4.2. Ornithin transcarbamylase deﬁciency
OTC deﬁciency is an X chromosome-linked disorder interfer-
ng in the ﬁrst two steps of the urea cycle. Its clinical expression is
ore severe in affected homozygous males. In heterozygous female
arriers, the clinical picture can range from lethal neonatal hyper-
mmonemia to almost asymptomatic adults, depending on the
utation, with variable enzyme activity and random inactivation
f the X chromosome [16]. The use of asymptomatic heterozy-
ous female donors for LRLT has been described by Japanese teams
ith a good outcome in both the donor and recipient [59,60]. Two
ecipients displayed peak values of urine orotic acid and orotidine
xcretion after an allopurinol load, as did the donors, suggest-
ng altered enzyme activity, but no episodes of hyperammonemia
ccurred postoperatively [59].
With respect to the X-linked OTC deﬁciency, the use of grafts
or LRLT from asymptomatic heterozygous female donors might be
onsidered as having a good outcome [60].
.4.3. Late-onset type II citrullinemia
Type II citrullinemia is an adult-onset hepatic deﬁciency of
rgininosuccinate synthetase characterized by elevated plasma
evels of citrulline and ammonia [61]. This can result in fulminant
yperammonemia with a poor prognosis. Long-term manage-
ent with dietary treatment includes protein restriction as well
s supplementation with sodium benzoate and essential amino
cids to prevent acute episodes of hyperammonemia. A failure of
edical treatment to maintain metabolic compensation can be
onsidered as an indication for LT on a “case by case” basis. The
se of heterozygous LRLT donors for auxillary partial orthotopic
iver transplantation (APOLT) has been reported by Japanese teams
62–64].
.5. Organic aciduria
Organic  acidurias are systemic deﬁciencies affecting the
etabolism of branched-chain amino acids and leading to the uri-
ary excretion of non-amino organic acids. The clinical phenotype
s variable, but neurological symptoms with encephalopathy and
erebral oedema are predominant. Despite corrective dietary man-
gement with protein restriction, patients remain at a high risk of
etabolic decompensation. The results of LT in these patients are
eterogeneous, due to the persistent extrahepatic synthesis of toxic
etabolites in some cases [1].
.5.1. Maple syrup urine disease
Even though there have been several reports of successful LT
n children with maple syrup urine disease using deceased donors
nd subsequent successful DLT with the native livers [31], the lit-
rature is very scarce concerning LRLT, and only two  cases have
een reported. One child died after LRLT from vascular complica-
ions in the graft, but no information regarding the genetic status
f the donor was reported [31]. In the second case, the donor
as the heterozygous mother; the recipient did not experience
etabolic decompensation and exhibited neurological improve-
ent at 13 months of follow-up [65]. Heterozygous living-related
onors might be an option in these cases, but more data on long-
erm follow-up are required.
.5.2.  Methylmalonic acidemia
Methylmalonic  acidemia is an inherited disorder affecting
ethylmalonil CoA, and is marked by an accumulation of methyl-
alonic acid in the body and the subsequent rapid development
f encephalopathy, brain oedema, seizures, and coma in newborns.
espite long-term dietary management, affected patients remain
t risk of metabolic decompensation and ketoacidosis. The results
f LT in these patients are poor because the levels of methylmalonicr Disease 47 (2015) 261–270 267
acid  do not decrease sufﬁciently to prevent the ongoing renal
and neurological damage [1]. There have been several reported
cases of LRLT involving heterozygote donors [58,59]: neurolog-
ical symptoms were improved in the recipients, but the need
for metabolism-correcting medication remained unchanged. Het-
erozygous donors might be considered in the context of LRLT, but
with uneven results among the recipients.
4.5.3. Propionic acidemia
The  mitochondrial enzyme proprionyl-CoA carboxylase is
involved in the metabolism of branched-chain amino acids. Patients
present with metabolic acidosis and hyperammonemia, resulting
in severe mental retardation. The overall prognosis is poor with
survival rates of just 41% [66]. LRLT from heterozygous donors was
performed in three cases in Japan and achieved only partial correc-
tion of the metabolic disorder [59] as the altered systemic enzyme
activity persisted. In our centre, we  performed a re-transplantation
for chronic rejection in a 25-year old recipient who had received a
ﬁrst transplant at the age of 8 years from a cadaveric donor, with a
left liver graft from her obligate heterozygous mother. The recipient
died on day 15 after re-transplantation, and thus donor follow-up
was uneventful at one year (Scatton O, unpublished data). Het-
erozygous donors in LRLT might be an option, but the procedure
will only achieve partial correction of the metabolic disorder.
4.6.  Erythropoietic protoporphyria
The  clinical picture of erythropoietic protoporphyria is dom-
inated by painful photosensitivity due to the presence of
protoporphyrin in the skin. The toxic effects on the liver of this
increased biliary protoporphyrin excretion are observed in a minor-
ity of patients, with a higher risk in homozygous subjects [67].
The condition is usually managed pharmacologically, but a small
number of patients may  require LT for end-stage liver disease.
Inheritance is autosomal dominant, and one case of LRLT using a
parental donor has been reported. However, no data are available
on the genetic status of the living-related donor, and outcome was
fatal in the recipient after 3.3 months, due to anastomotic biliary
leakage and candidosis [68].
4.7. Haemochromatosis
There is only one report of an adult-to-adult LDLT from a donor
carrying heterozygous mutations of both C282Y and H63D with
grade 1 mild intrahepatocellular haemosiderin deposition on the
liver biopsy [69]. LT using the right lobe was performed, with an
uneventful postoperative course in both donor and recipient. Liver
function tests after one year of follow-up were within the normal
range, but no long-term data or biopsy results regarding the graft
have been reported.
4.8.  Wilson’s disease
Wilson’s  disease is a rare copper storage disease that results in
an accumulation of copper, mainly in the liver, brain, cornea, and
kidneys [1]. The prevalence is 1 in 30,000 people, with a carrier rate
of 1 in 90 [1]. At presentation, the clinical symptoms may range
from acute liver failure to predominant neuropsychiatric manifes-
tations, and chronic liver disease leading to hepatic insufﬁciency
[70]. LRLT from obligate heterozygous donors have been widely
reported [58,68,71,72]. These donors presented with an interme-
diate copper metabolism capacity, but they were able to mobilize
their copper stores [73]. We  were not able to ﬁnd any reports of
affected recipients following the inadvertent use of heterozygous
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rafts in cadaveric LT, but it is likely that such recipients exist as
he carrier rate is important [73].
.9. Glycogen storage disease
There  are twelve recognized forms of glycogen storage disor-
ers [74] that involve the abnormal storage of glycogen in various
issues and affected organs such as the liver, kidneys, and intestinal
ucosa. The clinical picture presents with hepatomegaly, hypogly-
aemia, and seizures, often starting during the neonatal period. The
ong-term complications are growth retardation and hepatic ade-
omas with a risk of transformation into hepatocellular carcinoma.
ll types are autosomal recessive except for type IXa, the latter
eing an X-linked recessive disorder [75]. LT has been reported
n the context of type I, III, IV, and VI glycogen storage diseases
74]. The use of these livers in the context of CLT or DLT should
e discouraged because of the extensive involvement of the liver
arenchyma and hepatomegaly. LRLT using heterozygous donors
as been reported for type I and type III diseases and achieved
he correction of hypoglycaemic episodes and a normalization of
rowth [76,77].
.10.  Bilirubin metabolism disorders
.10.1. Crigler–Najjar syndrome
The  Crigler–Najjar syndrome is a disorder affecting bilirubin
etabolism and in the case of type I presents with severe jaundice
rom unconjugated hyperbilirubinemia, kernicterus, and neurolog-
cal sequelae, while in type II presents with mild jaundice and no
ernicterus. Type I syndrome requires LT during early childhood or
dolescence [1], while type II responds well to the administration
f phenobarbital. Four cases of LRLT in children with heterozy-
ous type I donors have been reported [78]. Three of these children
urvived, the longest reported follow-up being 34 months [78].
.10.2.  Progressive familial intrahepatic cholestasis
Progressive familial intrahepatic cholestasis (PFIC) is a group
f cholestatic diseases presenting with defective secretion of bile
cids, or other bile components, into liver bile canaliculi. Type 1
nd 2 are found in early childhood and type 3 in late childhood,
eading to HCC and portal hypertension. LT is an established treat-
ent option for this indication [1]. LRLT from heterozygous donors
n PFIC 2 has been reported to achieve a signiﬁcant improvement
n clinical symptoms among recipients, as well as age-appropriate
rowth [79]. More heterogeneous results have been reported in
he case of PFIC 1, and thus more long-term data on outcomes are
ecessary [80].
.10.3.  Alagille syndrome
The  Alagille syndrome is an autosomal-dominant disease
allmarked by bile duct paucity with jaundice, pruritus, and pro-
ression to biliary cirrhosis, usually requiring LT. LRLT is possible
fter careful evaluation of the donor bile ducts to rule out any bile
uct paucity [81,82].
.11.  Alpha-1-antitrypsin deﬁciency
Five cases of LRLT for alpha-1-antitrypsin deﬁciency have been
eported in the literature [83,84], but no details were given on the
onor’s genetic status or long-term follow-up of the recipients.
.12.  Tyrosinemia type I (also see Section 3.3.3)Since the introduction of nitisinone treatment, the need for LT
n tyrosinemia type I has dropped to 12%. LT does not completely
ure this enzymatic defect as the renal deﬁciency is not corrected
[r Disease 47 (2015) 261–270
[1].  Heterozygous relatives are not affected by the disease and LRLT
has been reported in this setting [58,68].
5. Conclusion
Liver grafts affected by rare metabolic disorders can be consid-
ered as an option in the context of CLT, DLT, or LRLT in some selected
cases. The clinical scenarios differ markedly in each individual and
the clinicians caring for potential donors and recipients need to be
aware of the existence of these rare conditions.
In CLT, the inadvertent use of affected organs from undiagnosed
donors is unavoidable and the outcome may  be fatal in the recipient.
Diagnostic work-ups within a short time frame and in the absence
of guidelines limit the detection of these disorders prior to organ
donation.
In DLT and LRLT, any underlying metabolic disease will be
known and have been the subject of extensive screening in both
the donor candidate and the recipient. Heterozygous asymptomatic
ﬁrst-grade relatives may  be candidates for donation, but careful
consideration of possible operative risk factors is mandatory. The
outcome will be strongly dependent on the underlying metabolic
disease and results in the recipient may  be unsatisfactory if the
systemic enzyme disorder persists.
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